VIVOS INC: management transactions · United States · SEC (Form 4)

About VIVOS INC

Vivos Inc. (ticker: RDGL) is a U.S.-based medical technology company with a profile that remains materially different from a mature commercial medtech group. In the latest SEC filings reviewed, the stock is described as quoted on the OTCQB marketplace under RDGL rather than on NYSE or NASDAQ. The company is organized in the United States and has its principal operating presence in Richland, Washington, in the U.S. Pacific Northwest. Its corporate history dates back to 1994, when it was incorporated as Savage Mountain Sports Corporation, later renamed Advanced Medical Isotope Corporation in 2006, and finally Vivos Inc. in 2017. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315226008813/partiiandiii.htm?utm_source=openai)) Strategically, Vivos operates in precision oncology and more specifically in intratumoral radiation therapy devices. Its core platform is a proprietary hydrogel-based yttrium-90 technology marketed under the RadioGel™ brand for human use and IsoPet® for veterinary applications. The company describes this as an injectable precision radionuclide therapy intended to deliver radiation directly inside the tumor, with the goal of limiting exposure to healthy surrounding tissue. In practical terms, the addressable use cases highlighted by the company are non-resectable and radiation-resistant tumors, alongside selected companion-animal cancers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315224025735/ex99-1.htm)) From an investment standpoint, Vivos should still be viewed as a development-stage company with limited revenues and a high execution risk profile. The SEC filings indicate recurring losses since inception and ongoing dependence on equity financing, debt financing, grants, and Regulation A+ offerings. The company qualified a new Regulation A+ offering in March 2026 for up to $75 million, following earlier offerings in 2023, 2024, and 2025. For investors in France, Belgium, or Switzerland, the key takeaway is that Vivos is primarily a regulatory and clinical milestone story rather than a company already driven by scaled commercial sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315226023146/form10-q.htm)) Its competitive appeal lies in a differentiated therapeutic concept: localized radiation delivery, potential outpatient administration, and a platform that could span both human and veterinary oncology. The company said it received FDA Breakthrough Device Designation in December 2023 and filed an Investigational Device Exemption submission in June 2024 to advance first-in-human clinical trials. More recent SEC disclosures in 2026 discuss preparations for human studies in the U.S. and India, together with the formation of Vivos Scientific India LLP to support manufacturing, clinical data generation, and eventual commercialization in India. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315224025735/ex99-1.htm)) Geographically, the business remains centered in the United States, with historical roots in Washington State and a current commercial emphasis on the animal-therapy market in the Northwestern U.S. Internationally, the company is still early in its expansion path, but India is now an explicit strategic focus through licensing, product transfer, and local development efforts. Overall, Vivos Inc. fits the profile of a speculative U.S. healthcare micro-cap: technologically interesting, potentially disruptive, but highly exposed to regulatory approvals, financing needs, and operational execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315226023146/form10-q.htm))